ImageneBio Inc(IMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.2 | Insider Own | 36.07% | Shs Outstand | 11.3M | Perf Week | -2.66% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | -8% | Insider Trans | -0.08% | Shs Float | 7.3M | Perf Month | -13.36% |
| Enterprise Value | -0.09B | PEG | - | EPS next Q | -0.8 | Inst Own | 34.1% | Short Float | 0.85% | Perf Quarter | -27.83% |
| Income | -0.05B | P/S | - | EPS this Y | 66.6% | Inst Trans | 3.49% | Short Ratio | 4.49 | Perf Half Y | -30.09% |
| Sales | 0.00B | P/B | 0.32 | EPS next 5Y | 27.01% | ROA | -37.73% | Short Interest | 0.06M | Perf YTD | -41.74% |
| Book/sh | 12.6 | P/C | 0.34 | EPS past 3/5Y | 24.93% 8.22% | ROE | -40.69% | 52W High | -55.82% ($9.10) | Perf Year | -51.86% |
| Cash/sh | 11.99 | P/FCF | - | Sales past 3/5Y | -62.86% -38.64% | ROIC | -36.29% | 52W Low | 3.61% ($3.88) | Perf 3Y | -90.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 31.98% | Gross Margin | - | Volatility(W/M) | 5.73% 4.72% | Perf 5Y | -96.88% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 21.47 | EPS Q/Q | 8.47% | Profit Margin | - | RSI (14) | 33.02 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.47 | Sales Q/Q | - | SMA20 | -5.89% ($4.27) | Beta | 0.83 | Target Price | $18 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/5 | SMA50 | -15.55% ($4.76) | Rel Volume | 0.3 | Prev Close | $4.05 |
| Employees | 15 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 38.24% - | SMA200 | -29.11% ($5.67) | Avg Volume(3M) | 0.01M | Price | $4.02 |
| IPO | 2021/3/26 | Option/Short | No/Yes | Trades | 83 | Volume | 4,141 | Change | -0.74% |
🧬 A US clinical-stage biotech company developing treatments for intractable immune diseases such as atopic dermatitis and alopecia areata through its proprietary 'OX40' targeted antibody technology. Through a strategic merger in 2025, the company is making a leap forward as a next-generation leader in the immune and inflammation (I&I) field.
Over the past 1 year, on the lower side
56% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
IMA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +66.6% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 34.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
USCA Xtrackers MSCI USA Climate Action Equity ETF 3.5B 
USCL iShares Climate Conscious & Transition MSCI USA ETF 2.8B 
PABU iShares Paris-Aligned Climate Optimized MSCI USA ETF 2.5B 
KLMN Invesco MSCI North America Climate ETF 2.5B 
FINA Fidelity MSCI North American Subset Index ETF 2.3B It ranks #423 of 594 in the industry
Based on market cap of $46M.
FAQ
What kind of company is IMA?
IMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMA?
The market cap of IMA is approximately $46M, ranking 4,893 within its sector.
What is the 52-week high and low for IMA?
IMA has recorded a 52-week high of $9.10 and a low of $3.88.
